$SGHT

Sight Sciences, Inc.

CIK:0001531177|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 23,388	$ 19,564	$ 43,086	$ 37,072
Cost of goods sold	2,014	2,977	4,734	5,391
Gross profit	21,374	16,587	38,352	31,681
Operating expenses:
Research and development	2,512	4,387	5,058	8,817
Selling, general and administrative	22,750	23,867	49,595	48,390
Total operating expenses	25,262	28,254	54,653	57,207
Loss from operations	(3,888)	(11,667)	(16,301)	(25,526)
Investment income	678	1,026	1,419	2,174
Interest expense	(1,290)	(1,284)	(2,557)	(2,547)
Other income (expense), net	82	24	53	(115)
Loss before income taxes	(4,418)	(11,901)	(17,386)	(26,014)
Provision for income taxes	28	40	40	81
Net loss and comprehensive loss	$ (4,446)	$ (11,941)	$ (17,426)	$ (26,095)
Net loss per share attributable to common stockholders-basic	$ (0.08)	$ (0.23)	$ (0.32)	$ (0.51)
Net loss per share attributable to common stockholders-diluted	$ (0.08)	$ (0.23)	$ (0.32)	$ (0.51)
Weighted-average shares used in computing net loss per share attributable to common stockholders-basic	54,505,792	51,821,773	54,225,993	51,557,686
Weighted-average shares used in computing net loss per share attributable to common stockholders-diluted	54,505,792	51,821,773	54,225,993	51,557,686

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (17,426)	$ (26,095)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	197	274
Accretion of debt discount and debt issuance costs	476	465
Stock-based compensation expense	5,816	8,085
Noncash operating lease expense	225	241
Other	(125)	37
Changes in operating assets and liabilities:
Accounts receivable	(1,553)	1,112
Inventory	2,109	135
Prepaid expenses and other current assets	(1,348)	201
Other noncurrent assets	(153)	73
Accounts payable	555	385
Accrued compensation	(1,408)	(4,453)
Accrued and other current liabilities	(57)	392
Net cash used in operating activities	(12,692)	(19,148)
Cash flows from investing activities
Purchases of property and equipment	(79)	(210)
Net cash used in investing activities	(79)	(210)
Cash flows from financing activities
Proceeds from employee stock purchase plan purchases	476	434
Taxes paid on net share settlement of restricted stock units	(13)	(54)
Proceeds from exercise of common stock options	99	121
Net cash provided by financing activities	562	501
Net change in cash, cash equivalents, and restricted cash	(12,209)	(18,857)
Cash, cash equivalents, and restricted cash at beginning of period	92,230	120,357
Cash, cash equivalents, and restrcited cash at end of period	80,021	101,500
Restricted Cash	268	0
Cash and cash equivalents at end of period	79,753	101,500
Supplemental disclosure of cash flow information
Cash paid for interest	2,093	2,082
Operating lease expense	288	293
Cash paid for operating leases	314	307
Supplemental noncash disclosure of investing and financing activities
New operating lease assets obtained in exchange for operating lease liabilities	972	0
Acquisition of property and equipment included in accounts payable and accrued liabilities	$ 85	$ 23

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 79,753		$ 91,965
Accounts receivable, net of allowance for credit losses of $113 and $234 at June 30, 2026 and December 31, 2025, respectively	11,386		9,745
Inventory, net	5,695		7,767
Prepaid expenses and other current assets	4,606		3,257
Total current assets	101,440		112,734
Property and equipment, net	1,667		1,610
Operating lease right-of-use assets	1,185		438
Other noncurrent assets	580		518
Total assets	104,872		115,300
Current liabilities:
Accounts payable	1,898		1,343
Accrued compensation	4,665		6,074
Accrued and other current liabilities	3,805		3,610
Short-term debt, net	10,131		0
Total current liabilities	20,499		11,027
Long-term debt, net	30,645		40,300
Other noncurrent liabilities	834		31
Total liabilities	51,978		51,358
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025	0		0
Common stock, par value $0.001 per share; 200,000,000 shares authorized; 54,716,301 and 53,493,711 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	55		54
Additional paid-in-capital	454,988		448,611
Accumulated deficit	(402,149)		(384,723)
Total stockholders' equity	52,894	$ 53,903	63,942
Total liabilities and stockholders' equity	$ 104,872		$ 115,300